BridgeMD
Tests treatment safety and results for Non-small Cell Lung Cancer (NSCLC)
Official title Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
ClinicalTrials.gov ID: NCT07288177
What this study is testing
What is Rina-S?
Rina-S is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for non-small cell lung cancer (nsclc).
Also referred to as Rinatabart Sesutecan, PRO1184.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participant has histologically or cytologically confirmed metastatic or locally advanced NSCLC of adenocarcinoma histology, not amenable to curative...
- Participant must have radiological disease progression while on or after receiving the most recent regimen.
- Participants either may have actionable genetic alterations (AGAs) or no AGAs.
- Participant has measurable disease according to RECIST v1.1.
- Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1 within 7 days of Cycle 1 Day 1. Key
You likely can't join if
- (all study cohorts):
- Participant has NSCLC with histology other than adenocarcinoma
- Participant has a past or current malignancy other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of...
- Participants with newly identified or known unstable (eg, progressing brain metastases) or symptomatic central nervous system (CNS) metastases or...
The study team makes the final eligibility decision.
Where it's taking place
- Fountain Valley, California, United States
- Santa Rosa, California, United States
- Washington D.C., District of Columbia, United States
- Tampa, Florida, United States
- Lincoln, Nebraska, United States
- East Brunswick, New Jersey, United States
- Albany, New York, United States
- The Bronx, New York, United States
- Chapel Hill, North Carolina, United States
- Nashville, Tennessee, United States
- Fairfax, Virginia, United States
- Adelaide, Australia
- Hobart, Australia
- Hyde Park, Australia
- Murdoch, Australia
- Saint Leonards, Australia
- Shanghai, Pudong, China
- Tianjin, China
- Paris, France
- Pierre-Bénite, France
+ 19 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fountain Valley, California, United States; Santa Rosa, California, United States; Washington D.C., District of Columbia, United States; Tampa, Florida, United States; Lincoln, Nebraska, United States; East Brunswick, New Jersey, United States and 33 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.